NCT06118827View on ClinicalTrials.gov

A Study of HS-10518 in Healthy Female Participants

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

May 30, 2024

Study Completion Date

August 30, 2024

Conditions
Endometriosis
Interventions
DRUG

HS-10518

QD, orally for 7 days

DRUG

Placebo

QD, orally for 7 days

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY